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Abstract Arterial dysfunction has been documented in
patients with beta-thalassaemia major. This study aimed to
determinethequantityandproliferativecapacityofcirculating
CD133
+VEGFR2
+ and CD34
+VEGFR2
+ cells in patients
with beta-thalassaemia major and those after haematopoietic
stem cell transplantation (HSCT), and their relationships
with arterial function. Brachial arterial flow-mediated dila-
tion (FMD), carotid arterial stiffness, the quantity of these
circulating cells and their number of colony-forming units
(CFUs) were determined in 17 transfusion-dependent thalas-
saemia patients, 14 patients after HSCT and 11 controls.
Compared with controls, both patient groups had signifi-
cantly lower FMD and greater arterial stiffness. Despite
having increased CD133
+VEGFR2
+ and CD34
+VEGFR2
+
cells, transfusion-dependent patients had significantly re-
duced CFUs compared with controls (p=0.002). There was a
trend of increasing CFUs across the three groups with
decreasing iron load (p=0.011). The CFUs correlated with
brachial FMD (p=0.029) and arterial stiffness (p=0.02), but
not with serum ferritin level. Multiple linear regression
showed that CFU was a significant determinant of FMD (p=
0.043) and arterial stiffness (p=0.02) after adjustment of age,
sex, body mass index, blood pressure and serum ferritin
level. In conclusion, arterial dysfunction found in
patients with beta-thalassaemia major before and after
HSCT may be related to impaired proliferation of
CD133
+VEGFR2
+ and CD34
+VEGFR2
+ cells.
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Introduction
The importance of arterial dysfunction in patients with beta-
thalassaemia major is increasingly recognized. In these
patients, we and others have demonstrated endothelial
dysfunction as evidenced by reduced brachial flow-
mediated dilation [1, 2] and increased stiffness of the
carotid artery [1], ascending aorta [2] and abdominal aorta
[3]. Endothelial dysfunction in these patients has
important clinical implications on the stiffening of the
arterial tree, with the consequences of suboptimal
ventriculo-arterial interaction [4] and the development of
premature atherosclerosis [5, 6].
Understanding of the mechanisms of arterial dysfunction
in patients with beta-thalassaemia major is hence of
paramount importance. In patients with β-thalassemia/
haemoglobin E, an increased level of circulating endothelial
cells reflecting endothelial damage and denudation has been
demonstrated [7]. Repair of the denuded endothelium might
be instrumental for the restoration of endothelial function.
Endothelial progenitor cells (EPCs) have been regarded as
restorative cells that home to sites of endothelial damage
and denudation [8]. Furthermore, the activities of EPCs
have been shown to correlate with the functional integrity
of the endothelium [9].
In patients with beta-thalassaemia, markers of oxidative
stress have been reported to be increased [10], whilst in a
rodent model of iron overload, increased generation of
reactive oxygen species within the arterial wall has been
demonstrated [11]. Importantly, reactive oxygen species
may accelerate the onset of EPC senescence [12]. Taken
together, iron overload in patients with beta-thalassaemia
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DOI 10.1007/s00277-011-1302-4major may potentially result in arterial dysfunction via its
effects on the quantity and function of EPCs.
The definitions of EPC are nonetheless varied and
controversial [13–15], which result in the generation of a
complicated list of putative EPC immunophenotypes.
Whilst recent data suggest that CD133
+CD34
+ VEGF
receptor 2 (VEGFR2)
+ cells do not appear to be true EPCs
[13–15], CD133
+, CD34
+, or VEGFR2
+, or any combina-
tion of these immunophenotypes, have been commonly
used to enumerate putative EPCs [15]. Importantly, circu-
lating concentration of these cells have been correlated with
cardiovascular risks [16–18] and occurrence of cardiovas-
cular disease and events [19, 20].
This study aimed to determine the quantity and
proliferative capacity of circulating CD133
+VEGFR2
+ and
CD34
+VEGFR2
+ cells in patients with beta-thalassaemia
major and their relationships with endothelial function and
arterial stiffness. To further address the effect of varying
iron loads on these cell number and function, we compared
the findings in transfusion-dependent thalassaemia patients
with those in patients who had undergone haematopoietic
stem cell transplantation (HSCT) and in healthy control
subjects.
Materials and methods
Subjects
Seventeen patients with beta-thalassaemia major receiving
regular blood transfusion and 14 patients who had
undergone HSCT were recruited from the haematology
clinic. Eleven healthy subjects were recruited as controls.
The latter included adult volunteers, healthy siblings of
thalassaemia patients and individuals with functional heart
murmur or nonspecific chest pain or palpitation attending a
cardiac outpatient clinic for which no underlying organic
causes were identified.
All subjects rested for at least 15 min before cardiovas-
cular assessment as described below. The body weight and
height were measured and the body mass index was
calculated accordingly. Blood pressure in the right arm
was measured twice using an automatic oscillometric
device (Dinamap, Critikon, Inc.), and the average of two
readings was taken. The serum ferritin levels of all subjects
were also determined.
Assessment of arterial function
Endothelial function of the brachial artery was assessed
noninvasively by ultrasound examination of the vasodila-
tion response to endothelium-dependent stimulus, as previ-
ously reported [1]. The right brachial artery, proximal to the
antecubital fossa, was imaged longitudinally using the
linear array transducer of the Vivid 7 ultrasound machine
(General Electric, Horten, Norway). Flow-mediated
endothelium-dependent vasodilation was assessed by mea-
suring the brachial artery diameter at baseline and during
reactive hyperaemia. Reactive hyperaemia was induced by
deflating a cuff inflated to 300 mmHg for 4 min in the
forearm. The percentage of diameter change during reactive
hyperaemia was calculated. Low intra- and inter-observer
coefficients of variation for flow-mediated dilation have
previously been reported by our group [1].
The cross-sectional stiffness of the right carotid artery
was measured by calculating the stiffness index [5]. The
carotid artery segment about 1 cm proximal to the carotid
bifurcation on the right side was imaged using the linear
transducer, and the systolic and diastolic diameters were
measured. The stiffness index was calculated according to
the formula: [ln(systolic BP/diastolic BP)]/(δD/D),where
δD is the difference between systolic and diastolic
diameters and D is the mean diameter.
Quantification and proliferative assay of CD133
+ VEGF2
+
and CD34
+VEG2
+ cells
The circulating cells with the aforementioned predefined
immunophenotypes were quantified by flow cytometry as
previously reported [16]. Briefly, 100 μlo fp e r i p h e r a lb l o o d
was incubated with fluorescein isothiocyanate-conjugated
anti-CD34 (Becton Dickinson, NJ, USA), phycoerythrin-
conjugated anti-kinase insert domain receptor (R&D Sys-
tems) and allophycocyanin-conjugated anti-CD133 in the
dark at room temperature for 30 min. Control isotype
antibodies were obtained from Becton Dickinson. The red
blood cells were lysed by the addition of 2 ml of BD
FACS
TM lysing solution (Becton Dickinson). Fluorescence-
activated cell sorting analysis was performed using BD
FACSAria analyzer, and the data were analysed using
FlowJo software. Each analysis included all the events in
the lymphocyte region. The frequency of peripheral bloods
positive for the aforementioned reagents was determined by
a two-dimensional side scatter fluorescence dot-plot analysis
(Fig. 1). The percentages of positive cells were converted to
cells per millilitre of blood using the complete blood count.
Cell isolation and colony-forming assay were performed
as previously reported [17]. Mononuclear cells were
isolated using Ficoll-Paque
TM PLUS density-gradient cen-
trifugation from the peripheral blood of patients and
controls. Five million cells were cultured in a six-well
fibronectin-coated plate (Becton Dickinson) with CFU-Hill
Liquid Medium (STEMCELL Technologies, BC, Canada)
for 2 days, followed by harvesting of non-adherent cells.
One million cells were then transferred into a 24-well
fibronectin-coated plate (Becton Dickinson) for further
346 Ann Hematol (2012) 91:345–352culturing with fresh medium for 3 days. After 5 days of
plating, the cells were fixed and stained with Giemsa
staining solution. The number of colony-forming units
(CFUs) was enumerated in duplicate.
Statistical analysis
Data are presented as the mean ± SD or median and range,
where appropriate. Demographic characteristics, arterial
indices and the number of CFUs among the three groups
were compared by simple analysis of variance (ANOVA)
with post hoc comparisons by multiple t tests. The numbers
of CD133
+VEGFR2
+ and CD34
+VEGFR2
+ cells were
compared among the three groups using Kruskal–Wallis
test with post hoc comparisons by Mann–Whitney U test.
Relationships between arterial functional indices and CFUs
were determined by Pearson correlation analysis. Stepwise
multiple linear regression was used to identify significant
determinants of brachial flow-mediated dilation and carotid
arterial stiffness. A p value<0.05 was regarded as statisti-
cally significant. All of the analyses were performed using
SPSS version 11.5 (SPSS, Inc., Chicago, IL, USA).
Results
Subjects
The demographic data and clinical parameters of patients
and controls are summarized in Table 1. For the 17
transfusion-dependent thalassaemia patients, the types of
chelation therapy were deferiprone with deferoxamine in
eight, deferoxamine in four, deferasirox in three and
deferiprone in two patients. The 14 patients who had
undergone HSCT at a median age of 6.4 (range, 1.6–20.1)
years were significantly younger than transfusion-
dependent patients and controls (p<0.001). Regular phle-
botomy was performed in these transplanted patients until
serum ferritin level was reduced to <2,000 pmol/l. At the
time of study, 2 of the 14 patients were still receiving
regular phlebotomy. All of the patients did not have heart
failure clinically. The systolic blood pressure was lower in
patients with and without HSCT (p=0.009), whilst serum
ferritin level was expectedly the highest in transfusion-
dependent patients (p<0.001) compared with patients after
HSCT and controls.
Fig. 1 Two-dimensional side scatter fluorescence dot-plot analysis of the frequency of peripheral blood cells positive for CD133, CD34
and VEGFR2
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Compared with controls, transfusion-dependent patients (p
<0.001) and post-BMT patients (p=0.002) had significant-
ly lower brachial flow-mediated dilation (Fig. 2a). On the
other hand, carotid arterial stiffness was significantly
greater in transfusion-dependent patients (p=0.009) and
post-BMT patients (p=0.028) than controls (Fig. 2b). There
was a significant positive correlation between flow-mediated
dilation and carotid arterial stiffness (r=0.57, p<0.001).
Quantity and function of CD133
+VEGFR2
+
and CD34
+VEGFR2
+ cells
The number of these circulating cells had a skewed
distribution in the two patient groups (Fig. 3). There were
significant differences in the quantity of CD133
+VEGFR2
+
(p=0.049) and CD34
+VEGFR2
+ cells (p=0.01) among the
three groups as analysed by the Kruskal–Wallis test. Post hoc
comparisons revealed that the number of these cell types was
significantly higher in transfusion-dependent patients com-
pared with post-HSCT patients and control subjects (Fig. 3).
The proliferative capacity of these circulating cells was
assessed by its ability to form CFUs. A CFU is defined by a
cluster of central round cells surrounded by radiating spindle
cells (Fig. 4a). Significant differences in CFUs were found
among the three groups (ANOVA, p=0.038; Fig. 4b). Post
hoc comparisons showed that the number of CFUs was
significantly smaller in transfusion-dependent patients com-
pared with controls (p=0.002). For post-transplant patients,
their number of CFUs was similar to those of controls (p=
0.16). There was, however, a trend of increasing CFUs
across the three groups (p=0.011).
The number CFUs correlated positively with the magni-
tude of flow-mediated dilation (r=0.42, p=0.029) and
negatively with carotid arterial stiffness (r=−0.45, p=
0.02). There was, however, no correlation between serum
ferritin level and CFU counts (p=0.39). Multiple linear
regression analysis of the entire cohort was further
performed to identify significant determinants of flow-
mediated dilation and arterial stiffness. The dependent
variables included were age, sex, body mass index, systolic
and diastolic blood pressures, and serum ferritin level. The
only significant determinant identified was CFU counts for
both flow-mediated dilation (β=0.4, p=0.043) and carotid
arterial stiffness (β=−0.45, p=0.02).
Discussion
The present study demonstrates significant vascular dysfunc-
tion as characterized by impaired flow-mediated dilation and
arterial stiffness in not only transfusion-dependent patients
with beta-thalassaemia major but also in patients after HSCT.
In transfusion-dependent patients who have the greatest iron
load, impaired proliferation despite an increase in the number
of circulating CD133
+VEGFR2
+ and CD34
+VEGFR2
+ cells
is noted. Our data further suggest a dose-dependent effect of
iron load on the proliferation of these cells. Importantly, we
have shown that impairment of the proliferative capacity of
these cells in thalassaemia patients is associated with
vascular dysfunction.
Evidence of vasculopathy in patients with beta-
thalassaemia major is accumulating. The findings of endothe-
lial dysfunction and carotid arterial stiffening in iron-
overloaded transfusion-dependent patients concur with those
Table 1 Comparison of demographic and clinical parameters among transfusion-dependent thalassaemia patients, patients after HSCT,
and controls
Transfusion-dependent patients
(n=17)
Patients post-HSCT (n=14) Controls (n=11) p
Age (years) 26.9±6.0 17.8±7.0
b 26.2±4.0 <0.001
a
Sex (M/F) 7:10 5:9 5:6 0.88
Weight (kg) 48±8 42±10 61±14
b <0.001
a
Height (cm) 158±6 151±15 164±9
b 0.018
a
Body mass index (kg/m
2) 19±2 18±2 22±3
b 0.001
a
Systolic blood pressure (mmHg) 105±11 105±7 117±12
b 0.009
a
Diastolic blood pressure (mmHg) 67±13 64±7 66±6 0.64
Ferritin (pmol/l) Median: 4,383
b
(range, 2150–11866)
Median: 572
(range, 96–4672)
Median: 168
(range, 16–998)
<0.001
a
aStatistically significant
bp<0.05 by post hoc t test or Mann–Whitney U test (for ferritin level) compared with the other two groups
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21]. In patients after HSCT, however, data on vascular
function are scarce. In the only study published to date,
Limsuwan et al. [22] have reported significant arterial
intima–media thickening despite normal carotid arterial
stiffness in transplanted thalassaemia patients when studied
at a mean age of 10 years. In the present study, however, we
found that despite HSCT, our patients studied at a mean age
of 18 years had persistent endothelial dysfunction and carotid
arterial stiffening.
Despite regular phlebotomy, thalassaemia patients after
HSCT remain in a state of iron overload. In fact, iron
overload is a recognized common long-term issue in
patients with autologous and allogeneic HSCT [23, 24]. In
vivo studies have provided a link between iron load and
vascular dysfunction. Iron loading may reduce endothelium-
derived nitric oxide directly by decreasing endothelial and
inducible nitric oxide activity [25], and indirectly by
stimulating membrane lipid peroxidation to generate lipid
peroxyl radicals [26]. In mice overloaded with iron dextran,
Fig. 2 Box plots showing the magnitude of brachial arterial flow-
mediated dilation (a) and carotid arterial stiffness index (b) in patients
and controls
Fig. 3 Scatter plots showing the distribution of CD133
+VEGFR2
+
cells (a) and CD34
+VEGFR2
+ cells (b) in transfusion-dependent
patients, patients after haematopoietic stem cell transplantation
(HSCT) and controls
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arterial wall and impaired acetylcholine-induced endothelial-
dependent vasorelaxation have been shown [11].
Whilst previous studies have focused on assessing the
arm of endothelial damage in the generation of vascular
dysfunction in thalassaemia [1, 7, 15, 27, 28], repair of the
endothelial damage by EPCs may also be instrumental in
restoring normal endothelial function [29]. To our knowl-
edge, this is the first study to explore the associations
between cells with putative immunophenotypes of EPCs
and vascular function in transfusion-dependent thalassae-
mia patients and in patients after HSCT.
Although an unequivocal definition of circulating EPCs
by flow cytometry remains to be agreed upon, widely used
markers include CD34, VEGFR2 and CD133 [29]. None-
theless, recent studies suggest an important phenotypic and
functional overlap between cells with these immunopheno-
types, haematopoietic cells and mature endothelial cells
[15].
Whereas inverse associations between the quantity of
circulating CD133
+VEGFR2
+ and CD34
+VEGFR2
+ cells
and the occurrence of cardiovascular events [20], cardio-
vascular risk score [17], severity of coronary artery
disease [19], risk of peripheral vascular complications in
diabetic patients [16] and risk of development subclinical
atherosclerosis [18] have been widely reported, our
f i n d i n go fa ni n c r e a s ei nt h e s ec i r c u l a t i n gc e l l si no u r
transfusion-dependent patients with yet significant vascu-
lar dysfunction is intriguing. Several explanations can
perhaps be offered. Increased serum erythropoietin, docu-
mented in thalassaemia patients despite repeated blood
transfusion [30], has been shown to increase the mobili-
zation of circulating EPCs in both experimental models
[31] and human subjects [32]. Additionally, induction of
heme oxygenase-1 secondary to increased oxidative stress
[10] and iron overload [33]i nt h a l a s s a e m i am a ya l s op l a y
a role. In a rabbit model of aortic balloon injury, heme
oxygenase-1 has been shown to contribute to vascular
repair by increasing bone marrow-derived circulating
EPCs [34]. In our patients after HSCT, the reduction of
serum erythropoietin and heme oxgenase-1 might have
accounted for the normalization of number of circulating
CD133
+VEGFR2
+ and CD34
+VEGFR2
+ cells.
Although the number of these circulating cells has been
once regarded as a surrogate of function, discordance
between their quantity and CFUs is increasingly recognized
[35, 36]. Notwithstanding the suggestion of increased
mobilization of these cells in our transfusion-dependent
patients, which might be considered an intrinsic homeo-
static mechanism to restore endothelial function, their
proliferative capacity is limited and appears to worsen
progressively across the three groups (Fig. 4b). Although
there was a lack of an association between ferritin and
CFUs in this study, we did not measure non-transferrin-
bound iron that may be a better reflection of the free iron
potentially acting on these cells. It is noteworthy that whilst
cells of the CFUs express proteins similar to primary
endothelial cells, they also express myeloid progenitor cell
markers and mature into macrophages [13].
The exact mechanism of impaired cellular proliferative
capacity in our patients remains speculative. Increased
oxidative stress secondary to iron loading in patients with
beta-thalassaemia major [10] and in those after HSCT [24]
has been documented. A recent study showed an inverse
relationship between the level of oxidized low-density
lipoprotein and arterial endothelial function [37]. Nonethe-
less, the effect of oxidative stress on EPCs remains
controversial [38]. Compared with mature endothelial cells,
EPCs have been shown to be more resistant to oxidative
stress in relation to the high intrinsic expression of
Fig. 4 a Morphologic characteristics of a colony-forming unit (CFU).
b Number per high power field (HPF) in patients and controls
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tioned study did not, however, examine specifically the
effect of oxidative stress on proliferative capacity of
EPCs. On the other hand, other studies have shown that
endothelial colony-forming cells are highly sensitive to
oxidant stress [38]. It remains to be proven that increased
oxidativestresssecondarytoironloadinthalassaemiapatients
both before and after HSCTis the culprit for impaired cellular
proliferation found in this study. Nonetheless, the present
study has shed some light on the physiological significance of
reduced cellular proliferation on the arterial function in these
patients. Our findings are also consistent with the reported
relationship between colony number and endothelial function
in healthy and diseased population with varying cardiovascu-
lar risks [17, 19, 40].
Several limitations of this study warrant comments.
Firstly, the transfusion-dependent patients were put on
different regimens of iron chelation. It would have been
ideal to tease further the effect of various regimens on the
quantity and function of CD133
+VEGFR2
+ and
CD34
+VEGFR2
+ cells. Secondly, the number of subjects
studied is relatively small, and these findings can only be
regarded as preliminary. Thirdly, whereas the present study
is a cross-sectional one, a longitudinal study to monitor the
changes in the quantity and function of these cells and
corresponding changes in arterial function in patients before
and after HSCT would provide more insight on the impact
of iron load on the mobilization and proliferation of
these cells and the physiological implications on
vascular function. Fourthly, the age of transplanted
patients was younger. Nonetheless, this does not
abrogate the findings of the study as younger age
should be associated with better vascular [41]a n dE P C
[40] function. We have further performed multivariate
analysis to adjust for the possible confounding influence
of age on the vascular indices. Finally, we did not measure
erythropoietin in our patients as the hypothesis set priori
did not mandate its determination.
In conclusion, our findings suggest arterial dysfunction in
patientswithbeta-thalassaemiamajorevenafterHSCT,which
may perhaps be related in part to impaired proliferation of the
CD133
+VEGFR2
+ and CD34
+VEGFR2
+ cells in the milieu
of iron overload.
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